To allow eventual clinical translation of this DC-complete vaccine, we aimed to first unravel the phenotypic identity of the non-DCs and their potential immune modulatory functions on cDC and pDC potency in stimulating tumor-reactive CD8+ T cell and NK cell responses in vitro and in vivo. This evidence concerns the gene CD8A and neoplasm.